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Background 
Serious pathology as a cause of back pain has been described as rare, reported as 
1% of patients presenting to primary care [1,2]. However, the prevalence of serious 
pathology is likely to increase as cancer survival rates improve [3].  Better medical 
treatment of primary cancers means patients are living longer putting them at greater 
risk of developing metastatic disease [4].  
 
The second most common serious pathology to affect the spine after fracture, is 
metastatic bone disease (MBD) as a consequence of primary cancers [2]. The spine 
is one of the earliest sites affected especially in those with a history of breast and 
prostate cancer [4,5,6]. Metastases can affect any region of the spine: Cervical 20%; 
Thoracic 70%: Lumbar 20% [3]. The spread of MBD is not fully understood but its 
affinity to the spine is thought to be the result of hematogenous spread via venous or 
arterial routes. The complex spinal venous system, causes a slower venous flow 
allowing for deposits of tumour cells to occur and highly perfused vertebral bodies allow 
effective delivery of tumour cells [5,6]. 
  
The most common symptom of MBD is back pain, which is usually a benign condition 
with a prevalence of 80% in the general population. This makes it challenging for 
clinicians to differentially diagnose if the cause of a patients back pain is serious 
pathology. It is critical therefore that any clinician faced with a patient with back pain 
screen for serious pathology first as missing or delayed diagnosis has significant 
consequences for a patient’s prognosis including life expectancy, quality of life, 
medication tolerance and pain control [1,7,8].  
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Examples of red flags specifically related to cancer include night pain, weight loss and 
a past history of cancer [9]. Unfortunately the use of red flags is problematic as there 
is little or no high-quality evidence on their diagnostic accuracy with the exception of a 
past history of cancer [1,2].  The identification of serious pathology using a past history 
of cancer and back pain alone has been described as a blunt instrument if not used in 
conjunction with the type of cancer and the time since diagnosis [8]. For example, the 
risk of ovarian cancer spreading to bone is very small in comparison to breast cancer 
[10]. Equally, investigation of every person with back pain and a history of cancer would 
be extremely costly and detrimental to the patient, exposing them to unnecessary and 
potentially worrying investigations [10]. Clinicians are likely to use a combination of red 
flags to inform their suspicions of serious pathology. However, to date there is no 
evidence of the usefulness of red flags in combination and further work is needed to 
evaluate different combinations [1]. 
 
The red flags of night pain and weight loss used to detect serious pathology describe 
symptoms that potentially occur during the late stages of disease, yet the literature 
clearly states that early detection is critical for effective management and patient 
outcome [10,11,].   
 
MBD can occur at any time with 50% occurring within the first 5 years after a primary 
diagnosis of cancer with some developing, 10 years and beyond [12,13]. This 
sometimes protracted timeframe makes it challenging for both patients and clinicians 
to associate symptoms with possible metastases. Once MBD has developed it is 
considered incurable with a life expectancy of just 2 years following diagnosis [6]. 
However, life expectancy could increase if essential treatment was administered in the 
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early stages when there is less disease burden and the patient is able to tolerate 
medication [14]. 
 
Early identification would also have an impact on quality of life and could reduce the 
burden of treatment on Health Services by managing the disease, and maintaining a 
patient’s functional independence [11,15]. The consequences of untreated or late 
stage diagnosis can result in poor pain management and, in the worst case scenario, 
cause metastatic spinal cord compression [MSCC] which can lead to paralysis and 
compromise bladder, bowel and sexual function [16]. Further information on 
identification, diagnosis and management of MSCC can be found in Turnpenny et al 
[17] and NICE guidelines [18]. 
 
Currently it is unclear which red flags suggest the early presentation of MBD in the 
absence of cord compression. If red flags or clinical symptoms associated with early 
signs could be identified then clinicians would be able to ensure patients were 
managed appropriately in a timely manner resulting in better outcome. In addition, 
patients at risk could be informed of these symptoms so that they can act as their own 
advocates and present to an appropriate health care setting in a timely manner [19]. 
 
The following discussion focusses primarily on pain and night pain and then briefly 
discusses other symptoms of MBD. 
Bone pain is the most common symptom associated with MBD [11,20,21]. The pain is 
most likely to be caused by the destruction of bone and the stretching of the periosteum 
as the tumour grows [22]. Bone pain has been described as having a gradual onset, 
intermittent, dull in character, becoming constant and increasing in intensity with time 
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[23]. Pain is prevalent in the early stages of MBD with 70% of patients describing pain 
associated with the disease [4]. Three distinct types of MBD pain are described; [a] 
local pain, which patients describe as a persistent gnawing, aching pain; [b] 
mechanical pain, which is aggravated by movement and [c] radicular pain described 
as sharp shooting, stabbing and burning [3,5,16].  Ju et al [5] state the importance of 
understanding the type of pain a patient experiences as this may help to give clues to 
its etiology. However, these descriptors are not helpful in differentiating between those 
patients who have MBD and those who have benign back pain as they are common 
descriptors used by both groups.   
 A further type of pain referred to as ‘Incidence pain’, is described as severe, 
unpredictable and intermittent occurring suddenly related to movement with several 
episodes through the day [23]. However this type of presentation is usually prevalent 
in the late stages of the disease [24]. 
 
Band like trunk pain has been identified by a number of authors as a sign of MBD. 
Greenhalgh and Selfe [25] suggest that band like trunk pain could be an early sign of 
serious pathology with patients often reporting this initially as a vague symptom. 
Scuibba and Goksalan [3] refer to band like trunk pain as a feature of those who 
already have MSCC. Turnpenny et al  [17] concur and also link this symptom with signs 
of MSCC. Thus there is no consensus on whether band-like trunk pain is more likely 
to occur in the early or late stages of MBD, however it seems clear that clinicians 
should take the report of band-like trunk pain seriously. 
 
Several authors [3, 11, 22, 26] report that bone pain at night is the most ‘ominous’ sign 
in patients with MBD. Night pain is a red flag associated with serious pathology but it 
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is also a common finding in benign back pain and this challenges its usefulness as a 
sign of serious pathology [27]. ‘Ominous’ night pain signs and symptoms are those that 
are aggravated rather than relieved by lying [18]. The patient often describes the need 
to get up and walk to ease the pain during the night or that they are unable to sleep 
lying flat and routinely sleep upright in a chair. It is often night pain that drives a patient 
to seek help and present to emergency departments [28].  Interestingly this may not 
raise alarm bells in staff working in emergency departments as staff routinely working 
at night may not see the significance of the patients ‘night pain’.  
 
 
Greenhalgh and Selfe [25] identified ‘vague lower limb symptoms’ and ‘decreased 
mobility’ as symptoms associated with the early signs of serious pathology.  These 
symptoms have gone on to be used to identify the early signs of MSCC [10,17] but as 
yet they have not been specifically validated as early signs of MBD. As the disease 
progresses other clinical features manifest themselves with the second most common 
complaint being motor dysfunction followed by sensory dysfunction [3,5]. Systemic 
features may also become more apparent in particular the symptoms related to 
hypercalcemia which, are often vague and nonspecific and include fatigue, anorexia 
and constipation [20,21].  
 
Pain is an early sign of MBD but probably not a very useful early red flag as it mimics 
pain described by those with benign back pain. It is not until the disease progresses 
that it becomes easier to describe, becoming constant, unrelated to mechanical activity 
with increasing severity and worse at night [5,11,21]. However, patients with a past 
history of cancer reporting increasing or new symptoms are worthy of monitoring [5]. 
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Clearly not all patients with a past history of cancer will go onto develop MBD. What is 
not clear is the relative risk of developing MBD. There is a huge variability in the 
percentages described in the literature of those who will go on to develop MBD [30-
70%]. This variability is demonstrated by breast cancer where there are a number of 
subtypes and the risk is dependent on the type and the stage at presentation. For 
example a person diagnosed with Oestrogen Receptor Negative breast cancer is at 
greatest risk of developing MBD in the first 2 years of initial diagnosis whereas 
Oestrogen Receptor Positive breast cancer is likely to relapse many years later [13,29]. 
However, these figures are constantly changing due to better systemic adjuvant 
therapies and earlier diagnosis but there remains a substantial risk of recurrence or 
development of MBD [5,29]. 
 
 
Knowing which patients are at greater risk of developing MBD maybe helpful when 
assessing a patient who presents with back pain and a past history of cancer. (see 
Table 1). Risk factors for patients with a history of breast cancer are related to the type 
of breast cancer, the size of the tumour on diagnosis and lymph node involvement [10]. 
Similarly patients with a history of prostate cancer are at greater risk of MBD if the size 
of the tumour is large, the prostate specific antigen [PSA] level is high at time of 
diagnosis [greater than 10 ng/ml], and they have a high Gleason score of 7 or more. 
The Gleason grading system evaluates the prognosis via a biopsy and the score 
determines the grade and how aggressive the cancer is.  
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Patients may not be able to recall the type of cancer they were diagnosed with but 
usually recall the type of treatment they received. Patients treated with radiotherapy 
and/or chemotherapy are more likely to have had an aggressive type of cancer and 
are therefore at greater risk [30].  
 
Conclusion 
Patients with a past history of cancer that has an affinity to bone such as lung, prostate 
and breast cancer, who present with new symptoms that persist should be thoroughly 
evaluated with a high suspicion of MBD [5]. 
Many authors emphasise the importance of recognising early symptoms of MBD 
[11,14] but no empirical studies describe what these early signs are. Whilst (back) pain 
is the single most reported presenting symptom, it is difficult to differentiate MBD pain 
from benign back pain in the early stages of disease.  Following treatment for cancer 
it is very common for patients to worry that all aches and pains are linked to their 
previous cancer.  This can make it difficult for both patients and clinicians to know what 
to be particularly concerned about [31]. It is not necessary to investigate all patients 
with a past history of cancer and back pain as not all patients will go on to develop 
MBD. Currently there are no national guidelines on recognising the signs and 
symptoms of MBD for healthcare professions [32].  A safety netting process of closely 
observing patients at risk over time is reasonable and an important consideration in 
effectively managing these potentially serious cases [20]. Using knowledge of a 
patient’s risk of developing MBD and current red flags may help to raise a clinician’s 
index of suspicion and result in timely investigation and management of the patient. 
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There is a gap in our knowledge with regards to the early signs and symptoms of MBD 
which have implications for further research. It is proposed that patients hold the key 
to defining early signs and symptoms of MBD and further research should involve the 
experience of patients living with the disease. 
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Laura Finucane 
Table 1 Risk of bone metastases development (Oliver et al 2011) 
Reproduced with permission from The Journal of the Royal College of Physicians 
Edinburgh 2011 41:330-8. 
Low Risk Tumours High Risk Tumours 
Tumours that rarely spread to bone, 
e.g. central nervous system 
malignancy or ovarian cancer 
Tumours with a predilection for bony 
spread: prostate, breast, lung 
Tumours with a low risk of secondary 
dissemination, e.g. patients treated for 
breast cancer who at diagnosis had 
grade 1 tumours of special type, such 
as ‘tubular’ and/or small tumours of 
around 1 cm in diameter or less  
Patients treated for tumours of high 
grade and large size, which have 
shown evidence of a more malignant 
phenotype, such as local lymph node 
spread or lymphovascular invasion 
primary 
Tumours’ that cannot spread, e.g. 
premalignant conditions such as 
ductal carcinoma in situ of breast 
(DCIS) 
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